ClinicalTrials.gg
RecruitingNCT07002476EAST-LDLUpdated Sep 2, 2026

Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion

A Phase 3 interventional study of guideline-recommended SoC and Recaticimab (intensive) in Stroke, sponsored by Shanghai East Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's title name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai East Hospital · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
978
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 750 studies in Ischemic Stroke with a site in China — 377 open to participants now, 396 under way, 76 of them phase 3. Ischemic Stroke · China.

Planned enrollment
108th of 563
978 · median 266
Started
2025
with 106 others
Phase 3
109 of 750
63 open now
Primary completion
2027-03
later than 192 of 395 live
Registered
562nd of 750
by date

Among the 750 studies in Ischemic Stroke with a site in China, this one is the 108th largest by planned enrollment of the 563 interventional ones that give a count, is one of 107 that started in 2025, is one of 109 in phase 3, reaches primary completion later than 192 of the 395 other live ones, and was the 562nd registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

377 of the 750 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

372 more — sign in →

All 377 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 750 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

EAST-LDL is a prospective, multicenter, randomized, open-label clinical trial with blinded endpoint assessment evaluating whether early intensive lipid lowering with the PCSK9 inhibitor recaticimab, administered before endovascular therapy, improves functional outcome in patients with acute ischemic stroke due to anterior-circulation large-vessel occlusion. Participants are randomized to recaticimab plus guideline-recommended standard of care or standard of care alone. The primary outcome is favorable functional outcome, defined as a modified Rankin Scale score of 0-2 at 90 ± 7 days.

Read the detailed description

EAST-LDL is an investigator-initiated, prospective, multicenter, randomized, open-label clinical trial with blinded endpoint assessment conducted at approximately 20 stroke centers in China. Adults with acute ischemic stroke due to anterior-circulation large-vessel occlusion who are planned to undergo endovascular therapy within 24 hours of symptom onset or last known well are randomized 1:1 to the PCSK9 inhibitor group or the control group. Participants assigned to the PCSK9 inhibitor group receive guideline-recommended standard of care plus recaticimab 450 mg administered subcutaneously after randomization and before the first thrombectomy pass, whereas participants assigned to the control group receive guideline-recommended standard of care alone.

The original target sample size was 652 participants. The protocol prespecified one sample-size re-estimation after approximately 50% of the initially planned participants had completed the 90-day primary outcome assessment. Following the prespecified re-estimation, the independent Data and Safety Monitoring Board recommended at its third meeting on August 3, 2026 that the total sample size be increased by 50%, from 652 to 978 participants, in accordance with the predefined adaptive rules. No unblinded treatment results were disclosed to the investigators or other members of the blinded study team. The current target sample size is therefore 978 participants.

The primary outcome is favorable functional outcome at 90 ± 7 days, defined as a modified Rankin Scale (mRS) score of 0-2. Secondary efficacy outcomes include the ordinal distribution of mRS scores, National Institutes of Health Stroke Scale (NIHSS) score and change from baseline, low-density lipoprotein cholesterol (LDL-C) goal attainment and change from baseline, changes in inflammatory markers, severe disability, all-cause mortality, recurrent ischemic stroke, new hemorrhagic stroke, major adverse cardiovascular events, and health-related quality of life assessed using the EuroQol 5-Dimension questionnaire. Safety outcomes include symptomatic intracranial hemorrhagic transformation, serious adverse events, and adverse events of special interest. The 90-day mRS outcome is assessed centrally by an independent Outcome Assessment Committee blinded to treatment allocation.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • acute ischemic stroke
  • LDL-Cholersterol lowering
  • Endovascular Therapy
  • PCSK9
  • clinical trials
04

In context

Ischemic Stroke Reclassified

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

This study's planned enrollment of 978 is above the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Shanghai East Hospital is the lead sponsor of 95 studies on the registry; 50 are open to participants now.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (age 18 years and older);
  • Imaging diagnosis of acute ischemic stroke with anterior circulation large vessel occlusion (including: internal carotid artery, middle cerebral artery M1 and M2, anterior cerebral artery A1 and A2);
  • Planned to undergo endovascular intervention within 24 hours of symptom onset (or last known well time) according to local guidelines;
  • Provision of by the patient or his/her legally authorized representative (or by an appropriate agent according to local requirements).

Exclusion criteria

Exclusion Criteria:

  • ASPECTS score ≤5 on cranial CT imaging;
  • Pre-existing functional impairment, with mRS score >2;
  • Patients who are allergic to PCSK9 inhibitors;
  • Patients who have received PCSK9 monoclonal antibody within 1 month prior to enrollment or PCSK9 siRNA therapy within 6 months prior to enrollment;
  • Severe renal insufficiency, defined as estimated (eGFR) \< 15 mL/min/1.73m2 at final screening;
  • Active liver disease or hepatic dysfunction, defined as (AST) or alanine aminotransferase (ALT) > 3 times the ;
  • Severe, concomitant non-cardiovascular disease expected to reduce to less than 3 months;
  • Pregnant or lactating women;
  • Patients who are participating in other clinical trials;
  • Other conditions deemed unsuitable for inclusion in the clinical study by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
978 participants (estimated)

Study arms

  • Active comparator
    Control Group

    Guideline-recommended standard of care

    Drug: guideline-recommended SoC

  • Experimental
    Investigational Group

    Guideline-recommended standard of care+intensive lipid-lowering therapy

    Drug: Recaticimab (intensive)

Interventions

  • Drugguideline-recommended SoC

    Guideline-recommended SoC, including but not limited to oral lipid-lowering drugs, antiplatelet aggregation drugs, anticoagulant drugs, antihypertensive drugs, etc. It is to be determined by the investigator based on the subject's treatment needs.

  • 450 mg as three 150-mg subcutaneous injections after randomization and before the first thrombectomy pass. No additional PCSK9 inhibitor treatment is planned during the 90-day follow-up.

07

What researchers measure

Primary outcomes

  1. favorable functional outcome (defined as an mRS score of 0-2)

    the rate (%) of good functional outcome at 90 days (modified Rankin Scale \[mRS\] score 0-2). Modified Rankin Scale scores of 0 or 1 indicate good function without or with symptoms but not disability, score of 2 indicates slight disability but independence, 3 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.

    Time frame: 90 ± 7 days

Secondary outcomes

  1. mRS ordinal score

    Modified Rankin Scale scores of 0 or 1 indicate good function without or with symptoms but not disability, score of 2 indicates slight disability but independence, 3 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.

    Time frame: 90 ± 7 days

  2. Change from baseline in NIHSS score

    0-42, higher scores indicates worse severity

    Time frame: Day 14±3 days or before discharge

  3. Change from baseline in LDL-C

    Change from baseline in LDL-C at 14±3 days or before discharge

    Time frame: Day 14±3 days or before discharge

  4. Change in inflammatory markers

    Change from baseline in inflammatory markers at 14±3 days or before discharge;

    Time frame: Day 0, Day 14±3 days or before discharge

  5. Rate of severe disability(defined as mRS score of 3-5)

    Modified Rankin Scale scores of 0 or 1 indicate good function without or with symptoms but not disability, score of 2 indicates slight disability but independence, 3 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.

    Time frame: 90 ± 7 days

  6. Incidence of recurrent ischemic stroke events

    Incidence of recurrent ischemic stroke events

    Time frame: From randomization through Day 90

  7. Incidence of symptomatic intracranial hemorrhage transformation

    Incidence of symptomatic intracranial hemorrhage transformation within 24-48h;

    Time frame: Within 24-48 hours

  8. Incidence of patients with new hemorrhagic stroke

    Incidence of patients with new hemorrhagic stroke

    Time frame: From randomization through Day 90

  9. Incidence of patients with major adverse cardiovascular events

    Incidence of major adverse cardiovascular events (MACEs) within 90 days

    Time frame: From randomization through Day 90

  10. Number of patients with serious adverse events

    total number of serious adverse events reported during follow-up, according to standard definitions

    Time frame: From enrollment to 90 days

  11. Health related quality of life

    according to the EQ-5D

    Time frame: 90 ± 7 days

  12. NIHSS score

    0-42, higher scores indicates worse severity

    Time frame: at 14±3 days or before discharge

  13. LDL-C goal attainment rate

    LDL-C attained equal or lower than 1.8mmol/L (70 mg/dL)

    Time frame: at 14±3 days or before discharge

  14. Mortality rate

    Death within 90 days.

    Time frame: 90 ± 7 days

08

Study locations

1 of 1 sites recruiting
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.

Of 143 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 20 months is below that.

Counting every sponsor, half of 165 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2025
First posted
Jun 3, 2025
StartActual
Jun 19, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07002476
Lead sponsor
Shanghai East Hospital
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
Jun 19, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Gang Li, MD
Contact
ligang@tongji.edu.cn
86021-38804518 ext. 22107
Shanghai East Hospital
study chair · Tongji University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recaticimab

Start the discussion